The evolving role of bispecific antibodies in diffuse large B-cell lymphoma

This review article takes a deep dive into the use of bispecific antibodies (BsAbs) for the treatment of DLBCL, specifically, the structure, mechanism of action, clinical efficacy, and mechanisms of resistance. Currently, two BsAbs (glofitamab and epcoritamab) are approved in DLBCL, and combination strategies with chemotherapy, immunotherapy, and antibody-drug conjugates are currently under investigation with encouraging results.